CDC Director Resigns After Report On Her Financial Conflicts

Director of Centers for Disease Control and Prevention Tom Frieden addresses the media on the Ebola case in the U.S. at the Tom Harkin Global Communications Center on October 5, 2014 in Atlanta, Georgia. The first confirmed Ebola virus patient in the United States was staying with family members at The Ivy Apartment complex before being treated at Texas Health Presbyterian Hospital Dallas. State and local officials are working with federal officials to monitor other individuals that had contact with the confirmed patient.
Kevin C. Cox/Getty Images North America

Brenda Fitzgerald stepped down as the director of the Centers for Disease Control and Prevention on Wednesday morning following a Politico report on the conflicts of interest created by her financial holdings.

“This morning Secretary Azar accepted Dr. Brenda Fitzgerald’s resignation as Director of the Centers for Disease Control and Prevention.  Dr. Fitzgerald owns certain complex financial interests that have imposed a broad recusal limiting her ability to complete all of her duties as the CDC Director. Due to the nature of these financial interests, Dr. Fitzgerald could not divest from them in a definitive time period,” Health and Human Services spokesman Matt Lloyd said in a statement.

“After advising Secretary Azar of both the status of the financial interests and the scope of her recusal, Dr. Fitzgerald tendered, and the Secretary accepted, her resignation.  The Secretary thanks Dr. Brenda Fitzgerald for her service and wishes her the best in all her endeavors,” Lloyd added.

The news of Fitzgerald’s resignation came less than 24 hours after Politico published a report on Fitzgerald’s stock trades. Fitzgerald purchased stock in a tobacco company about one month after she took over as director of the CDC, an agency that urges Americans to stop smoking tobacco products. She later sold stock in that company, but was unable to sell other stocks that presented conflicts.

Fitzgerald had been forced to recuse herself from a number of issues that the CDC addresses, but she said she was unable to quickly sell those stocks. This prevented her from testifying at a January hearing and prompted scrutiny in Congress.

Masthead Masthead
Editor & Publisher:
Managing Editor:
Senior News Editor:
Assistant Editor:
Editor at Large:
Investigations Desk:
Senior Political Correspondent:
Front Page Editor:
Social Media Editor:
Editor for Prime & Special Projects:
General Manager & General Counsel:
Executive Publisher:
Head of Product:
Director of Technology:
Publishing Associate:
Front-End Developer: